← Eichor
Study identifier: NCT06169956 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

An Observational Study to Evaluate Neoadjuvant Nivolumab (OPDIVO®) in Combination With Platinum-Based Chemotherapy in Non-Metastatic Non-Small Cell Lung Cancer Participants in Germany

Condition: Resectable Non-small Cell Lung Cancer  ·  Sponsor: Bristol-Myers Squibb

PhaseN/A
Planned participants400
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

The purpose of this observational study is to collect and evaluate real-world data to assess the effectiveness of neoadjuvant nivolumab when given in combination with platinum-based chemotherapy in participants with early-stage, resectable non-small cell lung cancer (NSCLC) in Germany

This description comes directly from the study's public registry record.

Talk to the study team

BMS Study Connect Contact Center www.BMSStudyConnect.com  ·  855-907-3286  ·  Clinical.Trials@bms.com

First line of the email MUST contain NCT # and Site #.

Always discuss trial participation with your own doctor first.

Locations (1)

Klinikverbund AllgaeuKempten (Allgäu), Bavaria, GermanyRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06169956